BiotechTube
Home/BioNTech/Prof. Christoph Huber, M.D.
PC

Prof. Christoph Huber, M.D.

Co-founder, Scientific Advisory Board Chair

BioNTech

Therapeutic Areas

OncologyInfectious Diseases

BioNTech Pipeline

DrugIndicationPhase
BNT327Advanced solid tumorsPhase 2/3
BNT116Non-small cell lung cancer (NSCLC)Phase 2
BNT122 (autogene cevumeran)Adjuvant pancreatic cancer, melanomaPhase 2
BNT113HPV16+ head and neck cancerPhase 2/3
BNT311 (GEN1046)Advanced solid tumorsPhase 2
BNT312 (GEN1053)Advanced solid tumorsPhase 1/2
BNT211CLDN6+ advanced solid tumorsPhase 1/2
BNT323 (DB-1303)HER2-expressing solid tumorsPhase 3

Leadership Team at BioNTech

PU
Prof. Ugur Sahin, M.D., Ph.D.
Chief Executive Officer
PÖ
Prof. Özlem Türeci, M.D.
Chief Medical Officer
JH
Jens Holstein, CPA
Chief Financial Officer
SM
Sean Marett, MBA
Chief Business and Commercial Officer
SP
Sierk Poetting, Ph.D.
Chief Operating Officer
View full BioNTech profile